Pharmaceutical Standards
Pharmaceutical standards are a comprehensive set of reference materials essential for ensuring the safety, efficacy, and quality of pharmaceutical products. This category includes standards for active pharmaceutical ingredients (APIs), which are the core components responsible for therapeutic effects. Additionally, it covers compounds and metabolites relevant to both the pharmaceutical and veterinary industries, providing benchmarks for the accurate measurement and analysis of these substances. Nitrosamine control standards are crucial for detecting and mitigating potentially harmful nitrosamines in drug formulations. Toxicology standards help assess the safety and potential adverse effects of pharmaceutical compounds. Furthermore, enzyme activators and inhibitors standards are vital for research and development, enabling precise studies of biochemical pathways and drug mechanisms. These pharmaceutical standards are indispensable tools for regulatory compliance, quality control, and research, ensuring that pharmaceutical products meet stringent safety and effectiveness criteria.
Subcategories of "Pharmaceutical Standards"
Products of "Pharmaceutical Standards"
1-Amino-2-(4-chlorophenylazo)naphthalene-5-sulfonamide
Ref: 3D-FA17432
1g | Discontinued | Request information | |
50mg | Discontinued | Request information | |
100mg | Discontinued | Request information | |
250mg | Discontinued | Request information | |
500mg | Discontinued | Request information |
Mevastatin hydroxy acid sodium salt
Ref: 3D-FM25992
10mg | Discontinued | Request information | |
25mg | Discontinued | Request information | |
50mg | Discontinued | Request information | |
100mg | Discontinued | Request information | |
250mg | Discontinued | Request information |
Penicillanic Acid
Ref: 3D-FP164053
10g | Discontinued | Request information |
1-(4-Chloro-1-hydroxy-naphthalen-2-yl)ethanone
Ref: 3D-FC51368
1g | Discontinued | Request information | |
2g | Discontinued | Request information | |
250mg | Discontinued | Request information | |
500mg | Discontinued | Request information |
4-Ethyl-1-naphthoic acid
Ref: 3D-FE23091
1g | Discontinued | Request information | |
2g | Discontinued | Request information | |
5g | Discontinued | Request information | |
10g | Discontinued | Request information | |
25g | Discontinued | Request information |
N-[2-(1H-Imidazol-5-yl)ethyl]-N'-(3-methylphenyl)urea
Ref: 3D-FI130837
1g | Discontinued | Request information | |
2g | Discontinued | Request information | |
5g | Discontinued | Request information | |
250mg | Discontinued | Request information | |
500mg | Discontinued | Request information |
Z-3-(2-naphthyl)-D-alanine
Ref: 3D-FN48885
1g | Discontinued | Request information | |
2g | Discontinued | Request information | |
5g | Discontinued | Request information | |
10g | Discontinued | Request information | |
25g | Discontinued | Request information |
4-Methyl-8-Dimethylaminomethyl Esculetin
Ref: 3D-FM74318
10mg | Discontinued | Request information | |
25mg | Discontinued | Request information | |
50mg | Discontinued | Request information | |
100mg | Discontinued | Request information | |
250mg | Discontinued | Request information |
Boc-L-citrulline 4-nitrophenyl ester
Ref: 3D-FB47905
1g | Discontinued | Request information | |
2g | Discontinued | Request information | |
5g | Discontinued | Request information | |
500mg | Discontinued | Request information |
Suprofen
Ref: 3D-FS27978
10mg | Discontinued | Request information | |
25mg | Discontinued | Request information | |
50mg | Discontinued | Request information | |
100mg | Discontinued | Request information | |
250mg | Discontinued | Request information |
3-Allyl-4-hydroxyacetophenone
Ref: 3D-FA54132
2g | Discontinued | Request information | |
5g | Discontinued | Request information | |
10g | Discontinued | Request information | |
25g | Discontinued | Request information |
4-(4-Nitrophenyl)-4H-1,2,4-triazole
Ref: 3D-FN131564
1g | Discontinued | Request information | |
2g | Discontinued | Request information | |
5g | Discontinued | Request information | |
250mg | Discontinued | Request information | |
500mg | Discontinued | Request information |
Ethyl 5-amino-1-(4-nitrophenyl)pyrazole-4-carboxylate
Ref: 3D-FE43639
1g | Discontinued | Request information | |
2g | Discontinued | Request information | |
5g | Discontinued | Request information | |
250mg | Discontinued | Request information | |
500mg | Discontinued | Request information |
Fmoc-O-methyl-D-tyrosine
Ref: 3D-FF49005
1g | Discontinued | Request information | |
2g | Discontinued | Request information | |
5g | Discontinued | Request information | |
10g | Discontinued | Request information | |
500mg | Discontinued | Request information |
rac methadone N-oxide
Ref: 3D-FR27537
2mg | Discontinued | Request information | |
5mg | Discontinued | Request information | |
10mg | Discontinued | Request information | |
25mg | Discontinued | Request information | |
50mg | Discontinued | Request information |
2-(3'-Bromophenyl)-1,3-dioxolane
Ref: 3D-FB02617
1kg | Discontinued | Request information |
1,4,5,8-Naphthalenetetracarboxdiimide
Ref: 3D-FN62838
1g | Discontinued | Request information | |
2g | Discontinued | Request information | |
5g | Discontinued | Request information | |
250mg | Discontinued | Request information | |
500mg | Discontinued | Request information |
3,5-Dinitro-L-tyrosine monohydrate
Ref: 3D-FD52227
1g | Discontinued | Request information | |
2g | Discontinued | Request information | |
5g | Discontinued | Request information | |
500mg | Discontinued | Request information |
5-Maleimido-eosin for fluorescence
Ref: 3D-FM44806
1mg | Discontinued | Request information | |
2mg | Discontinued | Request information | |
5mg | Discontinued | Request information | |
10mg | Discontinued | Request information | |
25mg | Discontinued | Request information |
1-[(4-Chloro-3-nitrophenyl)sulfonyl]piperidine
Ref: 3D-FC135433
1g | Discontinued | Request information | |
2g | Discontinued | Request information | |
5g | Discontinued | Request information | |
10g | Discontinued | Request information | |
500mg | Discontinued | Request information |